2162 — Keymed Biosciences Cashflow Statement
0.000.00%
- HK$8.97bn
- HK$6.49bn
- CNY354.10m
Annual cashflow statement for Keymed Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -168 | -819 | -3,893 | -304 | -356 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 93.8 | 681 | 3,654 | -129 | -37.7 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -6.95 | -0.187 | 2.83 | -5.67 | 21.1 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -68.4 | -119 | -215 | -402 | -304 |
Capital Expenditures | -62.3 | -19.9 | -173 | -280 | -383 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 4.28 | -93.2 | -1,863 | -366 | 851 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -58 | -113 | -2,036 | -646 | 468 |
Financing Cash Flow Items | 100 | 9.39 | -53.5 | -32.4 | -164 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 505 | 7.4 | 3,638 | -8.06 | 72.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 384 | -233 | 1,321 | -917 | 247 |